Related content

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 11, 2015-11 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 5, 2016-05 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Osteoarthritis Cartilage Defects: Does Size Matter?

By  

Current Rheumatology Reviews, Vol. 2, Iss. 4, 2006-11 ,pp. : 311-317

Bentham Science Publishers

Access to resources Recommend Favorite

Liver Volume in the Cirrhotic Patient: Does Size Matter?

By Hagan Michael   Sayuk Gregory   Lisker-Melman Mauricio   Korenblat Kevin   Kerr Thomas   Chapman William   Crippin Jeffrey  

Digestive Diseases and Sciences, Vol. 59, Iss. 4, 2014-04 ,pp. : 886-891

Springer Publishing Company

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 14, Iss. 2, 2017-01 ,pp. : 94-100

Bentham Science Publishers

Access to resources Recommend Favorite